Medical Digest & Congress Report

Professor Mazyar Shadman on the findings from a real-world, retrospective study that were presented during the 2023 ASH Annual Meeting: Autologous hematopoietic cell transplantation lowered relapse and progression rates and improved survival outcomes vs CAR T-cell therapy in patients with relapsed large B-cell lymphoma who experienced complete remission with interim treatment. Video: https://medic...

Professor Peter Hillmen on the combination of ibrutinib and venetoclax, at a duration determined by minimal residual disease, improved progression-free survival and overall survival vs fludarabine, cyclophosphamide, and rituximab in patients with treatment-naive chronic lymphocytic leukemia, according to findings from the phase 3 FLAIR trial that were presented at the 2023 ASH Annual Meeting. Vide...

Professor Andrew Srisuwananukorn's research revealed that an AI-powered machine learning algorithm, when examining digital whole-slide images of diagnostic bone marrow biopsies, accurately distinguished between prefibrotic primary myelofibrosis and essential thrombocythemia with an 92.3% accuracy rate, according to data presented at the 2023 ASH Annual Meeting. Video: https://medicaldigest.org...

Professor Fabien Mueller explains preliminary results from an early-stage study presented at the American Society of Hematology meeting over the weekend provided some of the first clinical evidence supporting the use of CAR T-cell therapies to treat autoimmune diseases. Video: https://medicaldigest.org/scientific-contents/interview:cd19-targeted-car-t-cells-refractory-systemic-autoimmune-diseases

Professor Viktor Grünwald at ESMO 2023 had a lecture on prognostic factors of renal cell carcinoma and in a recent podcast analyzed the importance of side effect profiles of new treatment options in RCC. We asked him, considering all these data and the current guidelines, how he differentiates between various treatments. Video: https://medicaldigest.org/scientific-contents/interview:medical-treatm...

Professor Luis Paz-Ares explains the most important novelties in the field of lung cancer treatement after ESMO 2023. - Early stage trails: ADAURA, ALINA, CheckMate 816, Keynote 671, CheckMate 017 - Stage III trial: PACIFIC-6 - STAGE IV trials: LIBRETTO-431, MARIPOSA, MARIPOSA-2, TROPION-Lung01 Video: https://medicaldigest.org/scientific-contents/interview:lung-cancer-highlights-esmo-2023-congress...

Professor Stephen Nicholls summarizes the state of art lipid lowering therapy after ESC 2023. Video: https://medicaldigest.org/scientific-contents/interview:state-art-lipid-lowering-treatment-2023

Professor Alberto Zambon explains the significance of intensive lipid lowering therapy in cardiovascular risk reduction after ESC 2023. He highlights the importance of early combination treatment to achieve target LDL- Ch levels. His key messages can be guidance for all of us. Video: https://medicaldigest.org/scientific-contents/interview:importance-intensive-lipid-lowering-cv-risk-reduction-role-...

Professor Benjamin Besse shares his insight on novelties in lung cancer treatment presented at ESMO 2023 Congress. Topics mentioned are targeted therapies, antibody drug conjugates and immunotherapies. Video: https://medicaldigest.org/scientific-contents/interview:lung-cancer-highlights-esmo-2023-congress

Professor Karijn Suijkerbuijk shares with us some highlights from ESMO 2023 on Melanoma. On neoadjuvant treatments of cutaneous melanoma, a small but important study on mucosal melanoma, and novelties on uveal melanoma. Video: https://medicaldigest.org/scientific-contents/interview:melanoma-highlights-esmo-2023-congress

Camillo Porta shares his thoughts about the most important novelties in RCC treatment. Studies such as: - Belzutifan/LITESPARK studies: LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced ccRCC, LITESPARK-005 study comparing belzutifan to everolimus in patients with previously treated advanced ccRCC - Toripalimab/RENOTORCH: a randomized, open-label, phase...

Silke Gillessen explains the most important stories in GU cancers at ESMO 2023. Studies such as: - EV-302/KEYNOTE-A39 trial: Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy - CheckMate 901 trial: the first Phase 3 trial with an immunotherapy-based combination to show statistically significant and clinically meaningful surviva...

Professor Hope Rugo shares her insights on the breast cancer highlights of #ESMO23 meeting, and also how they apply them in clinical practice. This was a really interesting meeting for breast cancer, we heard a lot of updates about antibody drug conjugates , immunotherapy and endocrine therapy. - DESTINY-Breast04 trial: trastuzumab deruxtecan offers added benefit for patients with HER2-low breast...

Professor Daniel Heng shares his thoughts on the developments of the last few years in the field of mRCC. Video: https://medicaldigest.org/scientific-contents/interview:treatment-mrcc-real-world-settings

Professor Krishnansu Sujata Tewari explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. Thes...

Professor Ignace B. Vergote explains the results from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with tisotumab vedotin demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy. These are t...

Professor Paweł Sobczuk shares his thoughts on five interesting studies presented during #ESMO23. These groundbreaking studies is form different tumor types like breast cancer, lung cancer and prostate cancer. Video: https://medicaldigest.org/scientific-contents/interview:late-breaking-studies-esmo-2023

Professor Jeffrey Weber shares his thoughts on the novel techniques in the field of melanoma. Like 5-Year Efficacy and Biomarker Results from CheckMate 238 and KEYNOTE-942, a combination of pembrolizumab plus a novel mRNA-based vaccine based on personalised neoantigens from patients with high-risk resected melanoma. Video: https://medicaldigest.org/scientific-contents/interview:keynote-942-mrna-ba...

Professor Filippo Pietrantonio discusses the influence of primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab on KRAS G12C-mutated metastatic colorectal cancer. Video: https://medicaldigest.org/scientific-contents/interview:targeted-combination-wins-kras-positive-metastatic-colorectal-cancer

Professor Krishnansu Sujata Tewari explains the results from he INTERLACE phase 3 trial, assessed whether a short course of induction chemotherapy prior to chemoradiation could reduce the rate of relapse and death among patients with locally advanced cervical cancer. As part of an analysis of clinical data, the preliminary results will be presented at the European Society for Medical Oncology cong...

Professor Mary McCormack explains the results from the GCIG INTERLACE trial presented in a Presidential Symposium at the ESMO Congress 2023. Phase III trial findings reveal significant improvements in PFS and OS rates, although the population studied may not be wholly indicative of high-risk disease. Video: https://medicaldigest.org/scientific-contents/interview:induction-chemotherapy-added-chemor...

Professor Clara Montagut Viladot discusses the primary results from the phase 3 CodeBreak 300 trial of sotorasib plus panitumumab in KRAS G12C–mutated metastatic colorectal cancer. Video: https://medicaldigest.org/scientific-contents/interview:codebreak-300-trial-kras-g12c-mutated-mcrc

Professor Michiel van der Heijden presented the results of CheckMate 901, a phase III trial evaluating the combination of nivolumab plus gemcitabine/cisplatin versus gemcitabine/cisplatin alone for patients with previously untreated unresectable or metastatic urothelial carcinoma. He shares details on the design of the trial and the late-breaking results that he presented at ESMO 2023. Video: http...

Professor Nicolas Girard explains primary efficacy results from the phase 3 PAPILLON trial of amivantamab plus chemotherapy in EGFR exon 20 insertion–mutated advanced non–small cell lung cancer. Video: https://medicaldigest.org/scientific-contents/interview:mivantamab-plus-chemotherapy-new-first-line-standard-care-egfr-exon-20-insertion-mutated-advanced-nsclc https://medicaldigest.org/scientific-c...

Professor Laura Locati highlights findings from phase 3 LIBRETTO-531 trial, that has demonstrated the superiority of selpercatinib, a highly selective RET kinase inhibitor, over approved multikinase inhibitors in people with advanced RET-mutant medullary thyroid cancer. Video: https://medicaldigest.org/scientific-contents/interview:selpercatinib-improves-outcomes-ret-mutant-medullary-thyroid-cance...